Key result
Supraventricular tachycardia has a prevalence of 2.29 per 1,000 persons, with women having twice the risk and individuals over 65 having over 5 times the risk of developing the condition.
This review summarizes the epidemiology, diagnosis via 12-lead ECG, and standard treatment of paroxysmal supraventricular tachycardia using EP study and catheter ablation.
The best available evidence indicates that the prevalence of supraventricular tachycardia (SVT) in the general population is 2.29 per 1,000 persons. Women have twice the risk of developing paroxysmal supraventricular tachycardia (PSVT) compared to men. Individuals aged >65 years have >5 times the risk of developing PSVT compared to younger persons. Twelve-lead electrocardiograms (ECGs) obtained during both tachycardia and sinus rhythm may reveal the etiology and help diagnose SVT. It is important to conduct a 12-lead ECG to differentiate tachycardia mechanisms according to whether the atrioventricular (AV) node is an obligate component. Invasive electrophysiologic (EP) study and catheter ablation have become a standard treatment for SVT, in addition to being an acute medical treatment. Diagnostic EP study complications are rare, but can be life threatening.
No takes yet. Share an insight, caveat, or question.
Yoo Ri Kim (2016) conducted a review in Supraventricular tachycardia. Supraventricular tachycardia has a prevalence of 2.29 per 1,000 persons, with women having twice the risk and individuals over 65 having over 5 times the risk of developing the condition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: